Skip to main content
Erschienen in: Obesity Surgery 7/2009

01.07.2009 | Research Article

Serum Phenylalanine Concentration as a Marker of Liver Function in Obese Patients Before and After Bariatric Surgery

verfasst von: Julian Swierczynski, Tomasz Sledzinski, Ewa Slominska, Ryszard Smolenski, Zbigniew Sledzinski

Erschienen in: Obesity Surgery | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Human obesity is associated with increased serum phenylalanine concentration, which is probably caused by liver dysfunction related to liver steatosis. This study examines whether improvements of liver function after bariatric surgery is associated with a decrease of serum phenylalanine concentration caused by an increase of phenylalanine metabolism.

Method

Serum phenylalanine and alanine aminotransferase (an independent predictor of liver steatosis) concentrations as well as several parameters related to obesity were measured in 16 obese patients (seven men and nine women) before and 6 months after vertical banded gastroplasty. Ten (six men and four women) lean, healthy subjects served as controls.

Results

Obese patients before surgery had approximately twofold higher serum phenylalanine concentration than control subjects. The serum phenylalanine concentration decreased 6 months after bariatric surgery. Serum alanine aminotransferase (ALT) concentration was higher in obese patients before surgery, and decreased 6 months after bariatric surgery. Changes in serum phenylalanine concentration correlated positively with changes of ALT concentration (r = 0.75; p < 0.001). The body weight, BMI, HOMA-IR, serum triacylglycerol, LDL-cholesterol/HLD-cholesterol ratio, leptin, insulin, and glucose concentrations were higher in obese patients, and decreased 6 months after bariatric surgery. Serum HDL-cholesterol concentration was lower in obese patients before surgery than in control subjects and increased 6 months after surgery.

Conclusion

Results obtained indicate that bariatric surgery-induced weight loss had beneficial effects on several laboratory parameters including serum phenylalanine, ALT, lipid concentrations and insulin resistance. A strong positive correlation between serum phenylalanine and serum ALT concentrations suggests that deterioration of liver function in obese patients is contributing to a decrease in phenylalanine metabolism and consequently to the increase of serum phenylalanine concentration. One can suppose that serum phenylalanine concentration could be noninvasive marker of liver dysfunction associated with liver steatosis in obese patients.
Literatur
1.
Zurück zum Zitat Pearl RH, Clowes GH, Bosari S, et al. Amino acid clearance in cirrhosis. A predictor of postoperative morbidity and mortality. Arch Surg. 1987;122:468–73.CrossRefPubMed Pearl RH, Clowes GH, Bosari S, et al. Amino acid clearance in cirrhosis. A predictor of postoperative morbidity and mortality. Arch Surg. 1987;122:468–73.CrossRefPubMed
2.
Zurück zum Zitat Zello GA, Pencharz PB, Ball RO. Phenylalanine flux, oxidation, and conversion to tyrosine in humans studied with L [1-13C]phenylalanine. Am J Physiol. 1990;259:E835–43.PubMed Zello GA, Pencharz PB, Ball RO. Phenylalanine flux, oxidation, and conversion to tyrosine in humans studied with L [1-13C]phenylalanine. Am J Physiol. 1990;259:E835–43.PubMed
3.
Zurück zum Zitat Heberer M, Talke H, Maier KP, et al. Metabolism of phenylalanine in liver diseases. Klin Wochenschr. 1980;58:1189–96.CrossRefPubMed Heberer M, Talke H, Maier KP, et al. Metabolism of phenylalanine in liver diseases. Klin Wochenschr. 1980;58:1189–96.CrossRefPubMed
4.
Zurück zum Zitat Holm E, Sedlaczek O, Grips E. Amino acid metabolism in liver disease. Curr Opin Clin Nutr Metab Care. 1999;2:47–53.CrossRefPubMed Holm E, Sedlaczek O, Grips E. Amino acid metabolism in liver disease. Curr Opin Clin Nutr Metab Care. 1999;2:47–53.CrossRefPubMed
5.
Zurück zum Zitat Burke PA, Stack JA, Wagner D, et al. L (1-13C]-phenylalaniane oxidation as a measure of hepatocyte functional capacity in end-stage liver disease. Am J Surg. 1997;173:270–3.CrossRefPubMed Burke PA, Stack JA, Wagner D, et al. L (1-13C]-phenylalaniane oxidation as a measure of hepatocyte functional capacity in end-stage liver disease. Am J Surg. 1997;173:270–3.CrossRefPubMed
6.
Zurück zum Zitat Ishii Y, Suzuki S, Kohno T, et al. Patients with severe liver cirrhosis followed up by L- [1-13C]phenylalanine breast test. J Gastroenterol. 2003;38:1086–90.CrossRefPubMed Ishii Y, Suzuki S, Kohno T, et al. Patients with severe liver cirrhosis followed up by L- [1-13C]phenylalanine breast test. J Gastroenterol. 2003;38:1086–90.CrossRefPubMed
7.
Zurück zum Zitat Ishii Y, Suzuki S, Kohno T, et al. L- [1-13C] phenylalanine breath test reflects histological changes in the liver. J Surg Res. 2003;114:120–5.CrossRefPubMed Ishii Y, Suzuki S, Kohno T, et al. L- [1-13C] phenylalanine breath test reflects histological changes in the liver. J Surg Res. 2003;114:120–5.CrossRefPubMed
8.
Zurück zum Zitat Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepathology. 2003;37:1202–19.CrossRef Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepathology. 2003;37:1202–19.CrossRef
9.
Zurück zum Zitat Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048–58.CrossRefPubMed Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048–58.CrossRefPubMed
10.
Zurück zum Zitat Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:34.CrossRefPubMedPubMedCentral Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:34.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Papadia FS, Marinari GM, Camerini G, et al. Liver damage in severely obese patients: a clinical–biochemical–morphologic study on 1,000 liver biopsies. Obes Surg. 2004;14:952–8.CrossRefPubMed Papadia FS, Marinari GM, Camerini G, et al. Liver damage in severely obese patients: a clinical–biochemical–morphologic study on 1,000 liver biopsies. Obes Surg. 2004;14:952–8.CrossRefPubMed
13.
Zurück zum Zitat Shalhub S, Parsee A, Gallagher SF, et al. The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients. Obes Surg. 2004;14:54–9.CrossRefPubMed Shalhub S, Parsee A, Gallagher SF, et al. The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients. Obes Surg. 2004;14:54–9.CrossRefPubMed
14.
Zurück zum Zitat Moretto M, Kupski C, Mottin CC, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obes Surg. 2003;13:622–4.CrossRefPubMed Moretto M, Kupski C, Mottin CC, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obes Surg. 2003;13:622–4.CrossRefPubMed
15.
Zurück zum Zitat Liew PL, Lee WJ, Lee YCh, et al. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg. 2006;16:1584–93.CrossRefPubMed Liew PL, Lee WJ, Lee YCh, et al. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg. 2006;16:1584–93.CrossRefPubMed
16.
Zurück zum Zitat Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentration are associated with histologic improvement. Obes Surg. 2006;16:1278–86.CrossRefPubMed Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentration are associated with histologic improvement. Obes Surg. 2006;16:1278–86.CrossRefPubMed
17.
Zurück zum Zitat Talwalkar JA. Motion—all patients with NASH need to have a liver biopsy: arguments for the motion. Can J Gastroenterol. 2002;16:718–21.CrossRefPubMed Talwalkar JA. Motion—all patients with NASH need to have a liver biopsy: arguments for the motion. Can J Gastroenterol. 2002;16:718–21.CrossRefPubMed
18.
Zurück zum Zitat Laurin J. Motion—all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol. 2002;16:722–6.CrossRefPubMed Laurin J. Motion—all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol. 2002;16:722–6.CrossRefPubMed
19.
Zurück zum Zitat Chang Y, Ryu S, Sung E, et al. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53:686–92.CrossRefPubMed Chang Y, Ryu S, Sung E, et al. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53:686–92.CrossRefPubMed
20.
Zurück zum Zitat Felig P, Marliss E, Cahill GF. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969;281:811–6.CrossRefPubMed Felig P, Marliss E, Cahill GF. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969;281:811–6.CrossRefPubMed
21.
Zurück zum Zitat Caballero B, Finer N, Wurtman RJ. Plasma amino acids and insulin levels in obesity: response to carbohydrate intake and tryptophan supplements. Metabolism. 1988;37:672–6.CrossRefPubMed Caballero B, Finer N, Wurtman RJ. Plasma amino acids and insulin levels in obesity: response to carbohydrate intake and tryptophan supplements. Metabolism. 1988;37:672–6.CrossRefPubMed
22.
Zurück zum Zitat Clark JM, Alkhuraishi AR, Solga SF, et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res. 2005;13:1180–6.CrossRef Clark JM, Alkhuraishi AR, Solga SF, et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res. 2005;13:1180–6.CrossRef
23.
Zurück zum Zitat Swierczynski J, Korczynska J, Goyke E, et al. Serum hepatocyte growth factor concentration in obese women decreases after vertical banded gastroplasty. Obes Surg. 2005;15:803–8.CrossRefPubMed Swierczynski J, Korczynska J, Goyke E, et al. Serum hepatocyte growth factor concentration in obese women decreases after vertical banded gastroplasty. Obes Surg. 2005;15:803–8.CrossRefPubMed
24.
Zurück zum Zitat Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed
25.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed
26.
Zurück zum Zitat Palova S, Charvat J, Masopust J, et al. Changes in the plasma amino acid profile in anorexia nervosa. J Int Med Res. 2007;35:389–94.CrossRefPubMed Palova S, Charvat J, Masopust J, et al. Changes in the plasma amino acid profile in anorexia nervosa. J Int Med Res. 2007;35:389–94.CrossRefPubMed
27.
Zurück zum Zitat Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–5.CrossRefPubMed Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–5.CrossRefPubMed
28.
Zurück zum Zitat Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–7.CrossRefPubMed Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–7.CrossRefPubMed
29.
Zurück zum Zitat Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537–56.CrossRefPubMed Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537–56.CrossRefPubMed
30.
Zurück zum Zitat Nobili V, Manco M, Ciampalini P, et al. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur J Endocrinol. 2006;155:735–43.CrossRefPubMed Nobili V, Manco M, Ciampalini P, et al. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur J Endocrinol. 2006;155:735–43.CrossRefPubMed
31.
Zurück zum Zitat Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotixicity? Hepatology. 2002;36:403–9.CrossRefPubMed Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotixicity? Hepatology. 2002;36:403–9.CrossRefPubMed
32.
33.
Zurück zum Zitat Zabrocka L, Raczynska S, Goyke E, et al. BMI is the main determinant of the circulating leptin in women after vertical banded gastroplasty. Obes Res. 2004;12:505–12.CrossRefPubMed Zabrocka L, Raczynska S, Goyke E, et al. BMI is the main determinant of the circulating leptin in women after vertical banded gastroplasty. Obes Res. 2004;12:505–12.CrossRefPubMed
34.
Zurück zum Zitat Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142:547–59.CrossRefPubMed Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142:547–59.CrossRefPubMed
Metadaten
Titel
Serum Phenylalanine Concentration as a Marker of Liver Function in Obese Patients Before and After Bariatric Surgery
verfasst von
Julian Swierczynski
Tomasz Sledzinski
Ewa Slominska
Ryszard Smolenski
Zbigniew Sledzinski
Publikationsdatum
01.07.2009
Verlag
Springer New York
Erschienen in
Obesity Surgery / Ausgabe 7/2009
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-008-9521-z

Weitere Artikel der Ausgabe 7/2009

Obesity Surgery 7/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.